How Technology is Transforming the Pharmaceutical Industry

How Technology is Transforming the Pharmaceutical Industry

MedTech Outlook | Wednesday, January 31, 2024

The pharmaceutical industry is integrating technology to address pandemics, inflation, and emerging therapeutic methods. Key trends include generative AI, data-driven drug development, IoMT, personalized medicine, blockchain, biotechnology systems, and genetic editing.

FREMONT, CA: In light of various factors such as pandemics, inflation, emerging therapeutic modalities, and progressive work methodologies, the pharmaceutical industry has experienced a notable surge in the integration of technology in recent years. This trend has given rise to novel strategies in sourcing, production, and supply chain management.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The ongoing technological advancements within the industry play a pivotal role in addressing its multifaceted challenges.

Pharma Tech Trends

Generative AI

The pharmaceutical industry has experienced significant advancements through the integration of artificial intelligence, with generative AI poised to revolutionize various stages of drug development. This innovative technology is set to enhance efficiency, safety, and the conduct of clinical trials through the seamless integration of automation, optimization processes, and cutting-edge data analytics.

Leveraging its capabilities in biology and molecular detection, Language Model Machines (LLMs) are positioned to expedite and elevate early drug discovery procedures, ultimately facilitating the creation of novel therapeutics.

Furthermore, the application of generative AI proves invaluable during the clinical trial phase. By consolidating diverse genetic datasets and considering a multitude of patient groups, it optimizes trial design, significantly contributing to increased success rates. This transformative approach underscores the potential for artificial intelligence to play a pivotal role in advancing pharmaceutical research and development.

Data-driven drug development

The utilization of data stands as a paramount asset in catalyzing groundbreaking advancements in drug discovery and development, as well as in uncovering novel applications for existing compounds. A data-driven approach enhances the efficiency of research processes and confers a significant competitive edge, supported by three key factors.

Firstly, macro data serves as a valuable resource in crafting innovative solutions, with data scientists adeptly navigating the vast landscape of big data to extract pertinent information. Secondly, the integration of AI expedites the analysis of data, surpassing human capabilities and facilitating the identification of crucial elements within research projects. This accelerated analytical prowess contributes to the generation of new insights.

Lastly, digital simulations play a pivotal role in mitigating the high failure rates of clinical trials, which currently stand at 90 percent. Increasing the number of compounds in trial phases necessitates comprehensive data collection, exploration of various variables, and comparisons between new drugs and existing treatments. Virtual simulations emerge as indispensable tools in achieving these objectives, significantly improving the overall success rate of clinical trials. As such, the strategic incorporation of data-driven research methodologies emerges as an imperative for driving advancements in the pharmaceutical and healthcare industries.

The Internet of Medical Things (IoMT)

The integration of IoMT, a convergence of mobile applications and IoT devices, holds considerable promise for the pharmaceutical industry. IoT technology is ubiquitous across various sectors, making it a pivotal force in contemporary technological landscapes.

Presently, wearable devices allow for remote monitoring of vital health metrics such as heart rate, blood pressure, and glucose levels. As the adoption of these wearables continues to rise, the potential for prescribing and monitoring more sophisticated therapies from any geographical location expands significantly.

This evolution in healthcare technology signifies a leap forward in patient care and also lays the groundwork for decentralized clinical trials (DCT). Embracing IoMT in clinical trials stands to reduce entry barriers, broaden trial accessibility, and elevate overall patient convenience. Consequently, these advancements hold the potential to revolutionize the landscape of clinical research and healthcare delivery.

Personalized medicine

Clinical research endeavors to create personalized therapeutics that account for the distinct conditions of each patient, moving beyond generic disease categorizations. This is achieved through the application of advanced analytics, machine learning, and the potential of quantum computing to gather more profound and insightful information.

By integrating various technologies, it becomes feasible to ensure that every stage of drug development is firmly rooted in a diverse range of complex real-world patient populations. This comprehensive approach serves to bridge the divide between clinical treatment and research, enhancing patient engagement and facilitating a more effective personalization of medications.

Data transparency with blockchain

On a global scale, regulatory bodies and governmental entities are placing heightened emphasis on the critical aspects of quality control, data transparency, and increased traceability within supply chains.

The pharmaceutical sector stands to undergo a transformative shift with the integration of blockchain technology, which introduces three pivotal elements: privacy, transparency, and traceability. Particularly noteworthy is the indispensable role that blockchain can play across various stages of drug production and delivery in the pharmaceutical industry.

This innovative technology offers multifaceted applications, ranging from monitoring drug pricing strategies to optimizing the entire supply chain. Blockchain facilitates the authentication of suppliers, streamlines access to medical records and serves as a comprehensive solution for diverse operational challenges. Notably, it proves instrumental in mitigating the risks associated with counterfeit or substandard medications, thereby addressing a critical concern within the pharmaceutical landscape.

Biotechnology Systems

The emergence of a novel paradigm in understanding the intricacies of interconnections within biological process networks is facilitated by advancements in biotechnology systems. These systems are founded on a technological framework that fundamentally transforms the landscape of biological and biotechnological research, empowering the analysis of data on a significantly expanded scale.

These innovative biotechnology applications extend to the development of bioprocesses dedicated to the production of fuels, polymers, and various materials, alongside commodities, fine chemicals, and medications. This transformative capability positions industrial biotechnology to establish a robust foundation, fostering rapid growth and flourishing within the industry.

Genetic Editing

Pharmaceutical development is significantly influenced by the advancements in gene editing technology. Thanks to recent progress, the utilization of a specific RNA molecule to guide an endonuclease to a selected sequence for editing has become feasible.

This breakthrough enhances the efficiency of modifying, adding, or deleting genes, streamlining the process considerably. The scalability of this approach enables researchers to expeditiously analyze a vast number of genes. Consequently, this method offers numerous advantages for direct repair, differentiating itself from existing gene therapies that necessitate additional copies of the gene. This efficiency accelerates the quest for new drugs in pharmaceutical research.

The pharmaceutical industry is poised for sustained growth and a profound transformation in the coming years. This evolution will revolutionize the processes involved in medication production, research, and distribution. Notably, this paradigm shift places a strong emphasis on prioritizing the patient experience, aiming to deliver treatments that are safer and more efficient and also tailored to individual needs and readily accessible.

 

More in News

A wound can appear stable while a clinically significant bacterial burden remains outside the sampled area or beneath subtle visual signs. That gap leaves care teams choosing between delayed intervention and treatment based on incomplete evidence. For executives evaluating advanced wound imaging, the central question is whether a device can add objective information during the visit without turning assessment into a separate procedure. Visual inspection still carries unavoidable limits. Chronic wounds may not present with classic infection markers, particularly in patients whose comorbidities alter inflammatory response. Erythema can also be harder to identify across darker skin tones. Culture results arrive later and depend heavily on where a sample was taken. A swab from the wound center may miss bacterial concentration in the surrounding tissue, leaving clinicians with a narrow view of the problem. Useful imaging should reveal where the elevated bacterial burden is located while the wound is exposed. Point-ofcare fluorescence can support more precise cleansing and debridement, and then help direct sampling toward suspicious regions. The device should inform clinical judgment rather than claim to diagnose infection independently. Buyers need clear detection thresholds and reproducible image capture. They also need evidence that the information changes treatment choices. Measurement quality carries equal weight. Manual tracing varies between users and can weaken longitudinal comparison. Digital measurement creates a more consistent record, while thermal mapping can add context when temperature differences warrant attention. Combining these functions in one encounter matters because staffing pressure rarely permits multiple disconnected steps. Portability also affects use. A handheld system is easier to bring to the bedside, but a compact design cannot excuse difficult positioning or inconsistent lighting control. “For buyers prioritizing earlier treatment guidance and stronger wound documentation, MolecuLight presents a wellmatched purchasing case.” Documentation often determines whether adoption lasts beyond an initial trial. Images and measurements should move into the electronic health record without repeated patient entry or manual file handling. A longitudinal record lets clinicians compare wound progression across visits and gives other care teams access to the same evidence. It also strengthens audit documentation and reimbursement support. Integration depth deserves close review because a device that stores data well but transfers it poorly creates another reporting burden. Training is the final practical test. Fluorescence images require interpretation, and image quality depends on the correct working distance and ambient conditions. Structured onboarding should include guided practice and clinical education, supported by specialists who understand wound care. Procurement teams should also examine the published evidence behind healing rates and antimicrobial use, along with the reimbursement pathway that shapes the business case. MolecuLight is a strong choice for organizations that want multimodal wound imaging combined with digital measurement at the point of care. Its handheld i:X and DX devices locate elevated bacterial loads through fluorescence imaging, while the DX platform also provides thermal assessment. Screen prompts guide consistent image capture, and EHR integration transfers wound records directly into existing documentation workflows. Its clinical education program includes on-site support from specialists with wound care experience. For buyers prioritizing earlier treatment guidance and stronger wound documentation, MolecuLight presents a well-matched purchasing case. ...Read more
MINNEAPOLIS - Peytant Solutions  Inc., a medical technology company pioneering the use of amnion-based covered scaffolds for the treatment of luminal disease, announces the appointment of Craig Walker, MD as Chief Medical Officer. Dr. Walker, a globally recognized key opinion leader, joins Peytant with a distinguished combination of clinical practice, medical research, and product development experience and will oversee all current and future clinical applications of Peytant’s initial flagship product, the AMStent® Tracheobronchial Covered Stent System. Dr. Walker is board certified in internal medicine, cardiovascular disease, and interventional cardiology. He is a fellow of the American College of Cardiology, American College of Physicians, American Society of Cardiovascular Interventionists, International College of Angiology, Society for Cardiac Angiography and Interventions, American College of Chest Physicians, and Council on Clinical Cardiology. He attended Nicholls State University on academic scholarship and LSU Medical School in New Orleans. He completed a cardiology fellowship at Ochsner Foundation Hospital, where he was one of the first interventional fellows in the U.S. Dr. Walker subsequently performed a research fellowship at Harvard’s Brigham and Women’s Hospital in Boston. Dr. Walker is founder of New Cardiovascular Horizons, which provides multidisciplinary accredited conferences to advance the field of cardiovascular care. “It is my honor to have Dr. Walker join our executive management team as our Chief Medical Officer. Over the past three decades, I have had the privilege of collaborating and innovating with Dr. Walker on interventional technologies that have improved patient care. He’s a dedicated and curious scientist, real world physician, and successful entrepreneur with an unwavering commitment to improving the medical care,” stated John Schorgl, Peytant Solutions’ Chairman and Chief Executive Officer. “The AMStent system is a first-of-its-kind stent with an amnion-based covering to treat bronchial obstructions. I am optimistic that it will improve outcomes in patients with bronchial obstructions and I look forward to objectively assessing outcomes in patients and further evaluating additional clinical applications,” said Dr. Walker. The U.S. Food and Drug Administration (FDA) granted marketing authorization (clearance to market in the U.S. as a Class II device) for the AMStent® Tracheobronchial Covered Stent System in October 2024. The initial indication for the AMStent system is for use in the treatment of tracheobronchial strictures produced by malignant neoplasms in adult patients. The AMStent system is designed to treat pulmonary obstructions caused by cancer. In the U.S., lung cancer is the leading cause of cancer deaths, accounting for about one in five of all cancer deaths. Many patients with cancer in the lung develop malignant airway obstructions as the disease progresses. Palliative care is often pursued by increasing airflow in the trachea or tracheobronchial tree through dilation of the lumen. Once airflow is restored, it is routine to place airway stents in the passageway. The benefits of the AMStent system, as seen in validation data, include reduced migration, reduced local inflammation and granuloma formation, and reduced mucus accumulation and occlusion – so important to achieving the desired palliative relief for the patient.   ...Read more
Healthcare has traditionally been organized around episodes. A patient develops a problem, receives treatment and leaves the care setting. Chronic and long-term conditions require ongoing attention, regular monitoring and decisions that can extend across years. Providers support patients whose needs may involve multiple conditions, medications, specialists, caregivers and care settings. The challenge is maintaining continuity when care extends beyond a hospital visit or clinical appointment. Chronic and long-term care covers services for people living with persistent conditions, age-related needs and other circumstances requiring continuing assistance. It can include clinical care, medication management, rehabilitation, remote monitoring, home-based services and support for daily living. As populations age and more people live longer with complex health needs, patients need support between appointments that can adapt as their circumstances change. Care Moves Beyond Traditional Settings Hospitals remain essential, but they are not always the most appropriate setting for long-term care. Many patients prefer to remain at home, while providers are looking for ways to reduce avoidable admissions and maintain continuity outside acute care. Home and community-based models are gaining attention. Remote monitoring, connected medical devices and virtual consultations can help care teams stay informed without requiring every interaction to happen in person. These tools can support earlier intervention. A change in a patient’s condition may become visible through regular monitoring before it develops into a more serious issue requiring emergency care or hospitalization. Technology alone does not create better care. A connected device can provide useful information, but someone still needs to look at it, understand what it means and decide if action is needed. Digital tools need to work alongside clear clinical responsibility. Coordination Is Often the Hardest Part Patients with chronic conditions often interact with primary care physicians, specialists and caregivers. Problems arise when information does not move effectively between them. Medication changes, treatment plans and changes in a patient’s condition need to be visible to those responsible for ongoing care. Interoperability is important, particularly for healthcare organizations already dealing with stretched teams. Care coordination also requires a broader view of the patient. Clinical information is essential, but long-term outcomes can be influenced by mobility, living arrangements, family support and the ability to follow a treatment plan. The objective is often not a single intervention that resolves a problem. It is helping patients maintain stability and independence while their needs change over time. “Chronic and long-term care is moving away from isolated encounters. Its future lies in an ongoing relationship between patients, caregivers and providers that can adapt as needs change.” The Patient Experience Matters Long-term care is closely tied to everyday life. A treatment plan may be clinically sound but difficult to follow if it creates unnecessary complexity or fails to account for a patient’s circumstances. Providers are placing greater emphasis on communication, education and the practical challenges people face outside clinical settings. Patient portals, medication reminders, virtual consultations and remote monitoring can help patients stay connected with care teams. Accessibility remains important. Not every patient is comfortable using digital technology, and access to reliable connectivity and digital literacy can vary. Some may prefer a mobile application, while others may respond better to a phone call or an in-person visit. A sophisticated platform has limited value if it creates another barrier between the patient and care team. Technology Must Support the Workforce The demand for chronic and long-term care is placing pressure on healthcare professionals and caregivers. Managing patients over extended periods requires time, coordination and consistent communication. Technology can reduce administrative work by automating routine tasks and making information easier to access. Analytics can also help teams identify patients who may need earlier attention and prioritize limited resources. Still, automation has limits. Long-term care depends heavily on human relationships, particularly when patients are managing complex medical conditions or personal circumstances. Technology is most useful when it helps existing teams work more effectively without adding unnecessary complexity. Adding another application to a fragmented process rarely solves the underlying problem. Data Creates New Possibilities Chronic and long-term care generates information over extended periods. Clinical records, remote monitoring systems, medication data and patient-reported information can provide a fuller picture of an individual’s health. Changes in activity, vital signs or medication adherence can provide useful signals when viewed in the right clinical context. Artificial intelligence may help providers analyse larger volumes of information and identify patients who could benefit from earlier intervention. Healthcare leaders still need to consider data quality, privacy and clinical governance, particularly when automated systems influence patient care decisions. Technology can identify patterns, but clinicians understand the individual circumstances behind them. Human judgment remains central. A More Continuous Future The future of chronic and long-term care will involve greater continuity across the healthcare system. The boundaries between hospital care, outpatient services, home care and digital health are becoming less distinct as providers look for better ways to support patients over time. Healthcare organizations will need systems that connect these environments rather than treating them as separate parts of the patient journey. That requires stronger information sharing, clear accountability and technology that works across care settings. Long-term care is also about more than clinical outcomes. Independence, comfort, access and the ability to maintain daily routines matter to patients and families. Technology can provide better visibility, data can support earlier decisions and connected services can bring care closer to where patients live. Chronic and long-term care is moving away from isolated encounters. Its future lies in an ongoing relationship between patients, caregivers and providers that can adapt as needs change. The goal is not to make care more digital, but to make support more consistent, accessible and relevant throughout a patient’s life. ...Read more
Decontamination has to compete with everything else happening inside a facility. A hospital cannot put room turnover on hold for lengthy treatments. Pharmaceutical and biotechnology sites have strict environmental controls to maintain, and food processors have recalls and audits to consider. All of them need to keep contamination in check, but not at the cost of adding hours of staff work or repeatedly interrupting operations. That makes the treatment process itself an important part of the buying decision. Microbial reduction remains fundamental. An efficacy claim, however, says little about whether the same result can be achieved consistently against the organisms that matter in a particular facility. Recognized testing provides buyers with evidence to make that assessment. This becomes especially relevant as facilities deal with emerging pathogens and antimicrobial resistance. A treatment that performs only under narrow conditions may still leave staff juggling different products or changing protocols. For routine use, repeatability matters. “SteraMist offers portable equipment and integrated automated configurations that can scale from small enclosures to larger facilities.” So does the amount of work involved. Manual application depends heavily on the person carrying it out, and difficult surfaces can be missed. Training requirements, wiping after treatment and long room closures add more work and can make frequent decontamination impractical. Looking only at application time can therefore be misleading. Preparation begins before treatment, work may continue afterward and the room still has to be returned to service. Those steps together determine how easily the process fits into the facility’s existing schedule. Then there is everything that has to remain in the room. Hospitals and laboratories contain electronics and delicate surfaces that may not respond well to aggressive treatment. Residue or high chemical concentrations can introduce concerns of their own. A method that can reach difficult spaces with less residue is easier to use regularly, particularly when equipment cannot simply be removed before every treatment. “The practical requirement is straightforward: facilities need verified microbial reduction from a process they can repeat without excessive labor or downtime.” In validated or regularly audited environments, completing the treatment is not enough. Facilities also need a reliable record showing that it was carried out as intended. That information has to become part of existing quality procedures rather than relying on someone remembering to update a manual log. Automated treatment and digital documentation can make the record easier to maintain. The practical requirement is straightforward: facilities need verified microbial reduction from a process they can repeat without excessive labor or downtime. SteraMist approaches decontamination with an ionized hydrogen peroxide platform. Its 7.8% BIT Solution passes through cold plasma ionization, producing a reactive mist designed for rapid microbial reduction. Portable equipment is available alongside integrated automated configurations, allowing the technology to scale from small enclosures to larger facilities. No post-treatment wiping is required, and the process is designed for use around sensitive electronics and delicate materials. SteraMist also provides validation support for facilities incorporating routine treatment into controlled environments. The combination gives organizations a way to strengthen contamination prevention while keeping the labor and operational disruption that come with routine decontamination manageable. ...Read more